# A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

> **NCT00162123** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 248 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00162123
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2012-09
- **Final completion:** 2014-04
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2016-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162123, "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00162123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*